... cancer Docetaxel (combined with estramustine, zoledronic acid or ADT) versus Standard of Care (hormone therapy or ADT) View in own window No. of studies Study ...

... various hormone therapies on QOL are required.[ 112 ] ADT A national Medicare survey of men who had ... health. Activity. Worries about cancer and dying. Energy. ADT can cause osteoporosis and bone fractures. In a ...

... years) Median Difference (range) Physical Component Summary Score ADT 38.80 NR 46.0 NR NA (−8. ... NR −3.00 NR Mental Component Summary Score ADT 53.20 NR 52.0 NR NA (−3. ...

... versus 3D-CRT combined with androgen-deprivation therapy (ADT), 35 the data on overall survival, all-cause ... beam radiotherapy (EBRT) alone versus EBRT combined with ADT, 43 a single medium risk-of-bias RCT ...

... combined with hormone therapy (androgen deprivation therapy, or ADT). Other treatments In men who have hormone-sensitive ... good overall health, the treatment options are conventional ADT in combination with docetaxel and prednisone or ADT ...

... Evaluate frequency of use of androgen-deprivation therapy ( ADT ) for low-risk prostate cancer Design: Physician survey ... could also be developed as an RCT of ADT vs. delayed ADT . Population: Patients with low-risk, ...

... high-risk (48%) disease received androgen deprivation therapy (ADT). Data on the ADT treatment, used by each risk-group, were obtained ... 2016). People with metastases were assumed to receive ADT for 3 years and docetaxel for 6 3- ...

... with DNA repair defects had decreased responses to ADT: — BRCA2 : 16/319 (5.0%) — Time from ADT initiation to mCRPC (mo): Germline positive, 11.8 ( ... 1.9%) — BRCA1 : 4/419 (1%) — PALB2 : None ADT = androgen deprivation therapy; AR = androgen receptor; CSS = cause- ...

... MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008; ...